期刊
LETTERS IN DRUG DESIGN & DISCOVERY
卷 14, 期 8, 页码 974-984出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570180814666161121112417
关键词
Antidepressant; BDNF; depression; serotonin; STEP; TC-2153
资金
- Complex Program of SB RAS for Basic Science [II.2Pi/VI.50-3, 0324-2016-0009]
- Russian Foundation for Basic Research [16-34-00466]
Background: Depressive disorders are among four leading causes of burden among the most disabling medical illnesses and antidepressant drugs (AD) occupying leading positions in the worldwide pharmaceutical market. However, typical AD show prolonged delay, refractory and adverse side effects. Methodology: The review analyzes experimental data and theoretical models of possible antidepressant effect of benzopentathiepine, 8-(trifluoromethyl)-1,2,3,4,5 - benzopentathiepin-6-amine hydrochloride (TC-2153). The antidepressant effect of TC-2153 is based on its ability to inhibit striatal enriched protein tyrosine phosphatase (STEP)- an enzyme that plays a key role in the intraneuronal transduction of signals from receptors of classic neurotransmitters and the brain derived neurotrophic factor (BDNF). The mechanism underlying antidepressant effect of TC-2153 includes increase in production as well as intracellular effect of BDNF on neuronal survival and neurogenesis. Results and Conclusion: There is no visible mechanisms of delay, refractory and adverse side effects of TC-2153. Thus, TC-2153 is a promising drug of new generation of atypical AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据